Published in Science on November 30, 1990
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev (2000) 5.71
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol (2000) 5.28
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol (1994) 4.14
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 4.09
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol (1993) 4.04
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1991) 3.69
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J (1998) 3.12
How many more breast cancer predisposition genes are there? Breast Cancer Res (1999) 3.10
Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol (1994) 3.05
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99
The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J (1992) 2.97
Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol (1993) 2.91
Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A (1993) 2.89
Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol (2011) 2.85
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Two faces of p53: aging and tumor suppression. Nucleic Acids Res (2007) 2.78
A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A (1995) 2.70
Autophagy in malignant transformation and cancer progression. EMBO J (2015) 2.67
Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J (1996) 2.63
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol (1995) 2.62
Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA (2011) 2.61
A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell (2013) 2.60
Familial breast cancer. BMJ (1994) 2.54
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A (1998) 2.50
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci U S A (1995) 2.43
Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci U S A (1991) 2.43
Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol (1997) 2.40
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34
PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev (2000) 2.33
Perception of risk in women with a family history of breast cancer. Br J Cancer (1993) 2.32
Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A (2008) 2.22
ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci U S A (1993) 2.19
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer (2011) 2.18
Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer (1994) 2.14
Current status of genome-wide association studies in cancer. Hum Genet (2011) 2.14
Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer (1997) 2.14
Architecture of inherited susceptibility to common cancer. Nat Rev Cancer (2010) 2.14
The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet (2012) 2.13
Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer (2009) 2.13
The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma (2001) 2.10
Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res (1992) 2.07
Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol (1994) 2.06
Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol (2004) 2.01
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A (1999) 2.00
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol (1996) 1.99
Cancer as a metabolic disease. Nutr Metab (Lond) (2010) 1.98
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol (1994) 1.97
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect (1995) 1.95
The p53 pathway in breast cancer. Breast Cancer Res (2002) 1.94
p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A (1993) 1.93
p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A (1993) 1.93
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
Activation and activities of the p53 tumour suppressor protein. Br J Cancer (2001) 1.90
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A (1992) 1.87
Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol (1995) 1.85
Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol (2000) 1.84
Realizing the promise of cancer predisposition genes. Nature (2014) 1.84
Inhibition of viral and cellular promoters by human wild-type p53. J Virol (1992) 1.83
miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ (2009) 1.82
Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol (1993) 1.80
The genetics of breast and ovarian cancer. Br J Cancer (1995) 1.78
The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer (1994) 1.75
Analysis of p53 mutants for transcriptional activity. Mol Cell Biol (1991) 1.73
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature (1983) 11.57
Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17
Rising incidence of renal cell cancer in the United States. JAMA (1999) 9.57
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 8.96
Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res (1988) 7.30
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 6.54
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell (1992) 6.03
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol (2000) 5.28
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med (1996) 4.81
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Snuff dipping and oral cancer among women in the southern United States. N Engl J Med (1981) 4.33
Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med (1987) 4.12
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1997) 4.09
In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene (1993) 4.03
Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst (1972) 3.78
Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med (2000) 3.72
Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A (1987) 3.72
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1998) 3.66
Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. JAMA (1986) 3.63
Hox genes and the evolution of vertebrate axial morphology. Development (1995) 3.60
A New Influence on Chemically Induced Sarcomata. Science (1948) 3.54
Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst (1993) 3.52
Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol (1992) 3.41
Risk of cancer in renal-transplant recipients. Lancet (1973) 3.36
THE LIQUEFACTION OF SPONTANEOUS TUMORS OF THE MAMMARY GLAND IN MICE BY HEPTYL ALDEHYDE. Science (1938) 3.34
Cancer risk in users of calcium channel blockers. Hypertension (1997) 3.30
Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst (1996) 3.26
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environmental Health Perspectives;1979:71-79. Int J Epidemiol (2007) 3.13
A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control (2001) 3.13
Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet (1977) 3.05
A new dynamin-like protein, ADL6, is involved in trafficking from the trans-Golgi network to the central vacuole in Arabidopsis. Plant Cell (2001) 3.01
Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA (1997) 3.00
Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet (1972) 2.99
Clues to cancer etiology from studies of farmers. Scand J Work Environ Health (1992) 2.98
Sonic hedgehog and Fgf-4 act through a signaling cascade and feedback loop to integrate growth and patterning of the developing limb bud. Cell (1994) 2.98
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med (1979) 2.82
Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst (1996) 2.78
Recent cancer trends in the United States. J Natl Cancer Inst (1995) 2.76
Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet (1998) 2.74
Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA (1993) 2.71
The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA (1995) 2.68
Germ-line msh6 mutations in colorectal cancer families. Cancer Res (1999) 2.68
Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer (1999) 2.66
Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol (1998) 2.65
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med (1992) 2.64
Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci U S A (2001) 2.60
A population-based case-control study of childhood leukemia in Shanghai. Cancer (1988) 2.59
THE TREATMENT OF SPONTANEOUS TUMORS IN DOGS BY THE INJECTION OF HEPTYL ALDEHYDE. Science (1938) 2.57
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA (1998) 2.55
Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52
Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst (1969) 2.50
International trends and patterns of primary liver cancer. Int J Cancer (2001) 2.50
Tobacco use and prostate cancer: 26-year follow-up of US veterans. Am J Epidemiol (1991) 2.49
Validation and reproducibility of food frequency questionnaire for Korean genome epidemiologic study. Eur J Clin Nutr (2007) 2.46
Geographic patterns of lung cancer: industrial correlations. Am J Epidemiol (1976) 2.45
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (1998) 2.43
Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev (2002) 2.36
Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst (2000) 2.32
Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol (2001) 2.30
Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst (1969) 2.30
Declining lung cancer rates among young men and women in the United States: a cohort analysis. J Natl Cancer Inst (1989) 2.28
Cancer mortality among chemists. J Natl Cancer Inst (1969) 2.28
Induction of Tumors by 3:4:5:6-Dibenzcarbazole in Male Mice of the CBA Strain, which Develops Spontaneous Hepatoma. Yale J Biol Med (1938) 2.26
Hydrocele of the canal of Nuck in a girl: ultrasound and MR appearance. Br J Radiol (2004) 2.26
Sonic hedgehog is an endodermal signal inducing Bmp-4 and Hox genes during induction and regionalization of the chick hindgut. Development (1995) 2.25
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Fluoridated drinking water and the occurrence of cancer. J Natl Cancer Inst (1976) 2.19
A population--based case--control study of renal cell carcinoma. J Natl Cancer Inst (1984) 2.17
Control of a genetic regulatory network by a selector gene. Science (2001) 2.17
Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst (1998) 2.13
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13
Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst (1997) 2.12
Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst (1987) 2.12
Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst (1976) 2.11
Risk factors for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking. Int J Cancer (1994) 2.09
Prognostic significance of lymph node dissection in the treatment of malignant melanoma. Cancer (1970) 2.08
Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn (1998) 2.08